MEDP Q1 Deep Dive: Rising Cancellations and Bookings Lag Shape 2026 OutlookClinical research company Medpace Holdings (
NASDAQ:MEDP) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 26.5% year on year to $706.6 mil...
Medpace’s (NASDAQ:MEDP) Q1 CY2026 Sales Beat Estimates But Stock Drops 19.8%Clinical research company Medpace Holdings (
NASDAQ:MEDP) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 26.5% year on y...
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Medpace Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – MEDPNEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Medpace Holdings, Inc. (“Medpace” or the “Company”) (
NASDAQ: MEDP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After President Allegedly Oversaw Misleading Disclosures: Levi & KorsinskyLevi & Korsinsky, LLP notifies investors that Jesse J. Geiger, President of Medpace Holdings Inc. (
NASDAQ: MEDP), is named as a defendant in a securities class action covering purchases between April 22, 2025 and February 9, 2026. Find out if you qualify to recover losses from the MEDP securities action. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, April 21, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Medpace Holdings, Inc. (“Medpace” or “the Company”) (
NASDAQ: MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Medpace (MEDP) Q1 Earnings: What To ExpectClinical research company Medpace Holdings (
NASDAQ:MEDP) will be reporting earnings this Wednesday after the bell. Here’s what to look for. Medpace beat anal...
MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, April 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Medpace Holdings, Inc. (“Medpace” or “the Company”) (
NASDAQ: MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Medpace Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – MEDPNEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Medpace Holdings, Inc. (“Medpace” or the “Company”) (
NASDAQ: MEDP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, April 14, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Medpace Holdings, Inc. (“Medpace” or “the Company”) (
NASDAQ: MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Deadline Approaching: Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Law Offices of Howard G. Smith reminds investors of the upcoming June 8, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Medpace Holdings, Inc. (“Medpace” or the “Company”) (
NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”).
1 Mid-Cap Stock for Long-Term Investors and 2 We AvoidMid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
MEDP INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Medpace Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Action Lawsuit
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Medpace Holdings Inc. (
NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, both dates inclusive (the “Class Period”), have until June 8, 2026 to seek appointment as lead plaintiff of the Medpace class action lawsuit. Captioned Durbin v. Medpace Holdings Inc., No. 26-cv-00346 (S.D. Ohio), the Medpace class action lawsuit charges Medpace and certain of Medpace’s top executives with violations of the Securities Exchange Act of 1934.
MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, April 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Medpace Holdings, Inc. (“Medpace” or “the Company”) (
NASDAQ: MEDP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Law Offices of Howard G. Smith Encourages Medpace Holdings, Inc. (MEDP) Shareholders To Inquire About Securities Fraud Class ActionLaw Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Medpace Holdings, Inc. (“Medpace” or the “Company”) (
NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”). Medpace investors have until June 8, 2026 to file a lead plaintiff motion.
Securities Fraud Investigation Into Medpace Holdings, Inc. (MEDP) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzThe Law Offices of Frank R. Cruz announces an investigation of Medpace Holdings, Inc. (“Medpace” or the “Company”) (
NASDAQ: MEDP) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Investor Notice: Robbins LLP Informs Investors of the Medpace Holdings Inc. Class Action
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Medpace Holdings Inc. (
NASDAQ: MEDP) securities between April 22, 2025 and February 9, 2026. Medpace is a clinical contract research organization (CRO) focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.
Rosen Law Firm Urges Medpace Holdings, Inc. (NASDAQ: MEDP) Stockholders to Contact the Firm for Information About Their RightsRosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Medpace Holdings, Inc. (
NASDAQ: MEDP) between April 22, 2025 and February 9, 2026. Medpace describes itself as a “clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.”
